Two Sigma Investments LP Purchases 184,202 Shares of Alnylam Pharmaceuticals, Inc. (ALNY)
Two Sigma Investments LP raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 155.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 302,376 shares of the biopharmaceutical company’s stock after buying an additional 184,202 shares during the quarter. Two Sigma Investments LP’s holdings in Alnylam Pharmaceuticals were worth $38,417,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Bailard Inc. purchased a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $445,000. State of Wisconsin Investment Board lifted its position in Alnylam Pharmaceuticals by 428.6% during the fourth quarter. State of Wisconsin Investment Board now owns 86,131 shares of the biopharmaceutical company’s stock valued at $10,943,000 after buying an additional 69,837 shares during the period. WINTON GROUP Ltd purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at $10,633,000. California Public Employees Retirement System lifted its position in Alnylam Pharmaceuticals by 5.1% during the third quarter. California Public Employees Retirement System now owns 133,206 shares of the biopharmaceutical company’s stock valued at $15,650,000 after buying an additional 6,506 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in Alnylam Pharmaceuticals by 2.4% during the third quarter. Bank of New York Mellon Corp now owns 342,105 shares of the biopharmaceutical company’s stock valued at $40,194,000 after buying an additional 8,163 shares during the period. 92.44% of the stock is owned by institutional investors and hedge funds.
In related news, SVP Laurie Keating sold 6,249 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total value of $757,378.80. Following the completion of the sale, the senior vice president now directly owns 17,749 shares in the company, valued at approximately $2,151,178.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Michael Mason sold 36,745 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $131.59, for a total value of $4,835,274.55. Following the completion of the sale, the vice president now owns 6,352 shares of the company’s stock, valued at $835,859.68. The disclosure for this sale can be found here. Insiders sold a total of 57,994 shares of company stock valued at $7,527,653 over the last quarter. 4.30% of the stock is owned by corporate insiders.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at $144.16 on Wednesday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $46.90 and a twelve month high of $152.75. The company has a market capitalization of $14,185.22, a PE ratio of -26.65 and a beta of 2.67. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.23 and a quick ratio of 12.23.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing the consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative return on equity of 41.08% and a negative net margin of 545.95%. The business had revenue of $37.90 million during the quarter, compared to the consensus estimate of $19.31 million. During the same quarter in the previous year, the business posted ($1.32) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 116.6% compared to the same quarter last year. analysts predict that Alnylam Pharmaceuticals, Inc. will post -6.88 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Two Sigma Investments LP Purchases 184,202 Shares of Alnylam Pharmaceuticals, Inc. (ALNY)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2018/03/14/two-sigma-investments-lp-purchases-184202-shares-of-alnylam-pharmaceuticals-inc-alny.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.